Westchester Capital Management (New York)’s Aspire Biopharma ASBP Stock Holding History

Westchester Capital Management (New York)’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30	Closed	-$397K	–	243
2024 Q1	$397K	Hold	30	–	–	0.01%	179
2023 Q4	$393K	Hold	30	–	–	0.01%	205
2023 Q3	$420K	Buy	+30	New	+$387K	0.01%	231
2023 Q2	–	Sell	-636	Closed	-$8M	–	342
2023 Q1	$8M	Buy	636 +589	+1,253%	+$7.36M	0.24%	123
2022 Q4	$582K	Buy	+47	New	+$576K	0.02%	355

Other funds holding ASBP

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Westchester Capital Management (New York)'s ASBP Position: Q2 2024 in Review

Westchester Capital Management (New York) sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 30 shares — an estimated $397K sold.

Westchester Capital Management (New York) first reported a position in ASBP in Q4 2022 and held it in 5 quarters. The position peaked at $8M in Q1 2023. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

Westchester Capital Management (New York) reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
Westchester Capital Management (New York) sold 30 Aspire Biopharma shares in Q2 2024, an estimated $397K.
Westchester Capital Management (New York) first reported a position in Aspire Biopharma in Q4 2022 and held it in 5 quarters.
Westchester Capital Management (New York)'s Aspire Biopharma position peaked at $8M in Q1 2023.
3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on Westchester Capital Management (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.